tbuckley/cabot-search huggingface dataset:
Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck
Authors: F. Sassi, S. Cazzaniga, G. Tessari, L. Chatenoud, A. Reseghetti, L. Marchesi, G. Girolomoni, L. Naldi
Journal: British Journal of Dermatology (2008)

Journal Article Randomized controlled trial comparing the effectiveness of 308‐nm excimer laser alone or in combination with topical hydrocortisone 17‐butyrate cream in the treatment of vitiligo of the face and neck Get access F. Sassi, F. Sassi Centro Studi GISED Search for other works by this author on: Oxford Academic Google Scholar S. Cazzaniga, S. Cazzaniga Centro Studi GISEDDepartment of Mathematics, University of Milan, Italy Search for other works by this author on: Oxford Academic Google Scholar G. Tessari, G. Tessari Department of Dermatology, University of Verona, Italy Search for other works by this author on: Oxford Academic Google Scholar L. Chatenoud, L. Chatenoud Unit of Analytic Epidemiology, Mario Negri Institute for Pharmacological Research, Milan, Italy Search for other works by this author on: Oxford Academic Google Scholar A. Reseghetti, A. Reseghetti Department of Dermatology, Ospedali Riuniti, 24100 Bergamo, Italy Search for other works by this author on: Oxford Academic Google Scholar L. Marchesi, L. Marchesi Department of Dermatology, Ospedali Riuniti, 24100 Bergamo, Italy Search for other works by this author on: Oxford Academic Google Scholar G. Girolomoni, G. Girolomoni Department of Dermatology, University of Verona, Italy Search for other works by this author on: Oxford Academic Google Scholar L. Naldi L. Naldi Centro Studi GISEDDepartment of Dermatology, Ospedali Riuniti, 24100 Bergamo, Italy Correspondence: Luigi Naldi. E‐mail:luigi.naldi@gised.it Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 159, Issue 5, 1 November 2008, Pages 1186–1191, https://doi.org/10.1111/j.1365-2133.2008.08793.x Published: 01 November 2008
Pulmonary infiltrates in patients with malignancies: why and how neutropenia influences clinical reasoning
Authors: E. Azoulay
Journal: European Respiratory Journal (2008)

<h3>Objective</h3> The evidence of an association between calcium channel blockers (CCBs) and cancer is conflicting. The objective of the present study was to evaluate the risk of cancer (all, breast, prostate and colon cancers) in association with exposure to CCB. <h3>Methods</h3> This is a population-based cohort study in patients exposed to CCBs from across the UK, using two comparison cohorts: (1) patients with no exposure to CCB (non-CCB) matched on age and gender and (2) unmatched patients unexposed to CCB and at least one other antihypertensive (AHT) prescription. Cancer incidence rates computed in the exposed and the two unexposed groups were compared using HRs and 95% CIs obtained from multivariate Cox regression analyses. <h3>Results</h3> Overall, 150 750, 557 931 and 156 966 patients were included, respectively, in the CCB, non-CCB and AHT cohorts. Crude cancer incidence rates per 1000 person-years were 16.51, 15.75 and 10.62 for the three cohorts, respectively. Adjusted HRs (CI) for all cancers comparing CCB, non-CCB and AHT cohorts were 0.88 (0.86 to 0.89) and 1.01 (0.98 to 1.04), respectively. Compared to the AHT cohort, adjusted HRs (CI) for breast, prostate and colon cancer for the CCB cohort were 0.95 (0.87 to 1.04), 1.07 (0.98 to 1.16) and 0.89 (0.81 to 0.98), respectively. Analyses by duration of exposure to CCB did not show excess risk. <h3>Conclusions</h3> This large population-based study provides strong evidence that CCB use is not associated with an increased risk of cancer. The analyses yielded robust results across all types of cancer and different durations of exposure to CCBs.
Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase mu.
Authors: D A Bell, C L Thompson, J Taylor, C R Miller, F Perera, L L Hsieh, G W Lucier
Journal: Environmental Health Perspectives (1992)

Several genes involved in the metabolism of carcinogens have been found to be polymorphic in human populations and are associated with increased risk of cancer at some sites. This study focuses on the polymorphic enzyme glutathione transferase mu (GT mu). Smokers with low lymphocyte GT mu activity are at an approximately 2-fold higher risk for lung cancer and an approximately 3-fold higher risk for stomach and colon adenocarcinomas. Recent cloning and sequencing of the GST1 gene has allowed the development of convenient genotyping methods based on restriction fragment length polymorphisms (RFLP) or the polymerase chain reaction (PCR). The GST1 polymorphism has been shown to be a deletion of the gene locus. To detect the presence or absence of the gene we amplified exons 4-5 and/or exons 6-7 of the GST1 gene by PCR. PCR amplification produced bands of 215-bp or 273-bp from individuals with one or two copies of the GST1 allele and no band if the individual was homozygously deleted (0/0). In the exon 6-7 PCR, we co-amplified a 268-bp portion of the beta-globin gene as an internal reference standard for quantitative analysis of product yield. This allowed homozygote individuals (+/+) to be distinguished from heterozygotes (+/0). We have compared the GST1 genotype to lymphocyte GT mu activity measured on trans-stilbene oxide (TSO) in the lymphocytes of 45 individuals. Low GT mu activity (&lt; 67 pmole/min/10(7) cells) was strongly associated (24/24) with the GST1 0/0 genotype. With the exception of one individual, activities greater than 67 pmole/min/10(7) were associated with the presence of the GST1 allele (20/21). Individuals with the highest GT-TSO activity were found to be homozygous for GST1. (+/+), while heterozygotes (+/0) generally had lower activity, suggesting a gene dosage effect in lymphocytes.(ABSTRACT TRUNCATED AT 250 WORDS)
The speed comparison between the left and right side step with selected anthropometric measurements to total movement time in running to the side for use by volley ball female players of senior secondary schools of Himachal Pradesh
Authors: Virender Kumar, Surinder Kumar Sharma
Journal: British Journal of Sports Medicine (2010)

A study has been conducted on selected anthropometric variables of female volleyball players of senior secondary school level. The purpose of the study was the comparison between the left and right step with selected anthropometric measurements to total movement time in running to the side for use by the volleyball players. Sample consisted of selected 24 female senior secondary school level volleyball players. Selected anthropometric variables were used to secure the responses. These 22 variables included foot length, foot breadth, foot height, heel breadth, in step circumference, ankle height, ankle circumference, bowl of foot width, bowl of foot circumference, bowl circumference, buttock-knee distance, buttock-leg length, calf circumference, calf height, circumference of knee, knee height, knee height sitting, knee to knee width, leg length sitting, leg length without foot, length of lower leg and length of thigh. t Test was used to analyse the data and result shows that significant difference is recorded in the variables of heel breadth, ankle height and bowl height. The significant difference is recorded when comparison of speed of movement between left and right foot is made.
Lesson of the week: Tethered cord syndrome after myelomeningocoele repair
Authors: N u O. Jeelani, T. Jaspan, J. A G Punt
Journal: BMJ (1999)

Secondary tethering of the spinal cord after myelomeningo- coele repair is a remediable complication that requires prompt treatment

Although the incidence of neural tube defects has fallen appreciably in the past two decades, from 3.4/1000 live births and stillbirths in 1974 to 0.8/1000 in 1994, the decline seems to be levelling off.1 The reduction is partly attributable to the increased consumption of folic acid by expectant mothers and partly to improved detection of defects in utero, which has led to the termination of approximately 50% of these pregnancies.2 Current protocols for patient care and management mean that 85% of liveborn infants with neural tube defects are now expected to reach adulthood,3 creating a cohort of people who are vulnerable to certain long term complications. Current healthcare systems need to be aware of this vulnerability, and adequate provision must be made if additional preventable disabilities are to be avoided in these people.

Although specific complications of renal failure, skin breakdown, and shunt malfunction have been highlighted in recent reports,4 the importance of one particular complication—symptomatic secondary tethering of the spinal cord—may have been underemphasised. We report one such case in an adolescent girl who presented with acute deterioration of her neurological status 17 years after surgical closure of her myelomeningocoele.

A 17 year old girl presented with a constant dull backache and weakness in her legs that made her unable to bear …
Peripartum Cardiomyopathy
Authors: Gail D. Pearson, Jean-Claude Veille, Shahbudin Rahimtoola, Judith Hsia, Celia M. Oakley, Jeffrey D. Hosenpud, Aftab Ansari, Kenneth L. Baughman
Journal: JAMA (2000)

Peripartum cardiomyopathy (PPCM) is a rare life-threatening cardiomyopathy of unknown cause that occurs in the peripartum period in previously healthy women. In April 1997, the National Heart, Lung, and Blood Institute (NHLBI) and the Office of Rare Diseases of the National Institutes of Health (NIH) convened a Workshop on Peripartum Cardiomyopathy to foster a systematic review of information and to develop recommendations for research and education.Fourteen workshop participants were selected by NHLBI staff and represented cardiovascular medicine, obstetrics, immunology, and pathology. A representative subgroup of 8 participants and NHLBI staff formed the writing group for this article and updated the literature on which the conclusions were based. The workshop was an open meeting, consistent with NIH policy.Data presented at the workshop were augmented by a MEDLINE search for English-language articles published from 1966 to July 1999, using the terms peripartum cardiomyopathy, cardiomyopathy, and pregnancy. Articles on the epidemiology, pathogenesis, pathophysiology, diagnosis, treatment, and prognosis of PPCM were included. RECOMMENDATION PROCESS: After discussion of data presented, workshop participants agreed on a standardized definition of PPCM, a general clinical approach, and the need for a registry to provide an infrastructure for future research.Peripartum cardiomyopathy is a rare lethal disease about which little is known. Diagnosis is confined to a narrow period and requires echocardiographic evidence of left ventricular systolic dysfunction. Symptomatic patients should receive standard therapy for heart failure, managed by a multidisciplinary team. If subsequent pregnancies occur, they should be managed in collaboration with a high-risk perinatal center. Systematic data collection is required to answer important questions about incidence, treatment, and prognosis.
THE DISCOVER CE TRIAL: 6–MONTH OUTCOMES OF THE DIRECT FLOW MEDICAL TRANSCATHETER AORTIC VALVE
Authors: Antonio Colombo, Federico De Marco, Jean Fadajet, Francesco Maisano, Azeem Latib, Didier Tchétché, Silvio Klugmann, Giuseppe Bruschi, Klaudija Bijuklic, Charles J. Davidson, Thierry Lefevre, Joachim Schofer
Journal: Journal of the American College of Cardiology (2013)
Blood pressure and atherogenic lipoprotein profiles of fish-diet and vegetarian villagers in Tanzania: the Lugalawa study
Authors: Paolo Pauletto, Massimo Puato, Mario G Caroli, Edoardo Casiglia, Aharon E Munhambo, Giuseppe Cazzolato, Gabriele Bittolo Bon, Maria T Angeli, Claudio Galli, Achille C Pessina
Journal: The Lancet (1996)
Antibiotic Combinations
Authors: Wilfred F. Jones, Maxwell Finland, Clare Wilcox, Ann Najarian, Mildred W. Barnes
Journal: New England Journal of Medicine (1957)

SINCE the introduction of erythromycin, many antibiotics having a similar antibacterial spectrum and exhibiting crossresistance with it have been encountered in various laboratories that are conducting programs designed to discover new antimicrobial agents. Thus far, attempts to exploit such erythromycinlike agents have been made with only 3 of them. The first of these, carbomycin (Magnamycin), was soon found to have so little clinical activity as compared with erythromycin or with other available agents that its use has been almost completely abandoned.Two other new antibiotics have become available more recently: oleandomycin (PA 105, Matromycin, Romicil)1 in this country; and spiramycin . . .
Heart Failure Risk Across the Spectrum of Ankle-Brachial Index
Authors: Deepak K. Gupta, Hicham Skali, Brian Claggett, Rumen Kasabov, Susan Cheng, Amil M. Shah, Laura R. Loehr, Gerardo Heiss, Vijay Nambi, David Aguilar, Lisa Miller Wruck, Kunihiro Matsushita, Aaron R. Folsom, Wayne D. Rosamond, Scott D. Solomon
Journal: JACC Heart Failure (2014)
Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial.
Authors: R A Coutinho, N Lelie, P Albrecht-Van Lent, E E Reerink-Brongers, L Stoutjesdijk, P Dees, J Nivard, J Huisman, H W Reesink
Journal: BMJ (1983)

The efficacy of a heat inactivated hepatitis B virus vaccine, containing 3 micrograms hepatitis B surface antigen (HBsAg), was studied in a high risk group of 800 susceptible homosexual men by a randomised placebo controlled double blind trial. At the trial end point (21.5 months), 17 hepatitis B virus infections had occurred in vaccinated subjects (attack rate 4.8%) and 56 in subjects receiving a placebo (attack rate 23.8%). This reduction in the incidence of hepatitis B virus infections in vaccinated subjects was highly significant (p less than 0.0001). Two months after the first injection 72.3% of the vaccinated subjects had formed antibodies against hepatitis B surface antigen, and this percentage increased to 89% at four months. Maximum anti-HBs titres were reached five months after the first vaccination, the geometric mean titre being 107.6 mIU. Even vaccinated subjects with a low antibody response (greater than or equal to 1 and less than 10 mIU) were found to be protected from HBsAg-positive infections. The vaccine had no serious side effects.
Ampullary carcinoid tumors diagnosed by endoscopic ultrasound-guided fine needle aspiration in two patients with biliary and pancreatic duct obstruction
Authors: I. El Hajj, A. El Chafic, H. Cramer, M. Al-Haddad
Journal: Endoscopy (2011)

We present two cases of ampullary carcinoid tumors diagnosed and appropriately staged by EUS-FNA.
Lymphosarcoma of Small Intestine with Ileocolic Fistula
Authors: Stanley W. Tuell
Journal: JAMA (1960)

Lymphosarcoma of the small intestine is a rare disease. In Tacoma's two largest hospitals, which have a total capacity of 452 beds, in the last 10 years there has been only one case of lymphosarcoma of the small intestine: the one here reported. At Presbyterian Hospital in New York City, 13 cases were seen<sup>1</sup>during a 15-year period. Menne, Mason, and Johnston<sup>2</sup>could find only two such cases in 40,000 autopsies. Spontaneous fistula formation between the ileum and the sigmoid colon, without previous trauma from the surgeon's knife or a penetrating foreign body, is likewise an unusual, if not a rare, condition. Among diseases which can produce such a fistula, the foremost are regional enteritis, acute diverticulitis, and malignant neoplasms. In the case reported here the patient had a spontaneous ileocolic fistula, produced by a primary lymphosarcoma of the small intestine. This tumor appeared to be of multicentric
Evidence-Based Practice Guidelines From the US Preventive Services Task Force
Authors: Harold C. Sox
Journal: JAMA (1993)

Clinical practice guidelines are an important innovation to improve the quality of care by defining appropriate clinical practice.<sup>1</sup>A growing number of organizations are using evidence-based methods to develop practice guidelines.<sup>2</sup>This approach emphasizes the critical evaluation of evidence, rather than expert opinion, to define proper care. Evidence-based methods have been used for over a decade to develop guidelines on clinical preventive services, beginning with the work of the Canadian Task Force on the Periodic Health Examination in the late 1970s.<sup>3</sup><i>Clinical preventive services</i>include screening tests (eg, mammography), counseling interventions (eg, smoking cessation), and immunizations. See also p 2664. The need for evidence of effectiveness is never higher than when clinicians advise healthy people about preventive services rather than treating existing disease. Therefore, it is important to ensure that the benefits of preventive services (eg, a longer, healthier life) exceed their potential harms (eg, mislabeling, complications
Bullous pemphigoid induced by PUVA therapy IS THIS THE AETIOLOGY OF THE ACRAL BULLAE PRODUCED DURING PUVA TREATMENT?
Authors: JUNE K. ROBINSON, RICHARD D. BAUGHMAN, THOMAS T. PROVOST
Journal: British Journal of Dermatology (1978)

Journal Article Bullous pemphigoid induced by PUVA therapy IS THIS THE AETIOLOGY OF THE ACRAL BULLAE PRODUCED DURING PUVA TREATMENT? Get access JUNE K. ROBINSON, JUNE K. ROBINSON Section of Dermatology, Dartmouth‐Hitchcock Medical Center, Hanover, N.H. 03755, U.S.A., and Department of Dermatology, State University of New York at Buffalo Search for other works by this author on: Oxford Academic Google Scholar RICHARD D. BAUGHMAN, RICHARD D. BAUGHMAN Section of Dermatology, Dartmouth‐Hitchcock Medical Center, Hanover, N.H. 03755, U.S.A., and Department of Dermatology, State University of New York at Buffalo Search for other works by this author on: Oxford Academic Google Scholar THOMAS T. PROVOST THOMAS T. PROVOST Section of Dermatology, Dartmouth‐Hitchcock Medical Center, Hanover, N.H. 03755, U.S.A., and Department of Dermatology, State University of New York at Buffalo Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 99, Issue 6, 1 December 1978, Pages 709–712, https://doi.org/10.1111/j.1365-2133.1978.tb07067.x Published: 01 December 1978
Defining the human reference protein-coding gene set
Authors: Suganthi Balasubramanian, Lukas Habegger, Adam Frankish, Daniel MacArthur, Rachel Harte, Chris Tyler-Smith, Jennifer Harrow, Mark Gerstein
Journal: Genome biology (2010)

The number of coding genes in the human genome is still under debate [1]. Here, we present a proposal to define the human reference gene set that takes into account the inter-individual differences in gene numbers arising from gene inactivation events, such as premature termination or aberrant splicing due to nonsense SNPs or SNPs at essential splice sites respectively. We have analyzed SNPs (specifically nonsense SNPs and SNPs affecting essential splice sites) from 23 personal genomes and exomes. We see a wide range in numbers of SNPs in each of the categories surveyed. A large fraction of these SNPs are singletons. Using a data set of high-confidence SNPs obtained by intersecting SNPs from dbSNP and the personal genomes, we identify a common set of 279 genes predicted to be pseudogenic (non-functional) in some individuals and functional in others.

We focused on two key questions arising from these considerations: (i) Which criteria should be used for inclusion and exclusion of genes from the reference set? (ii) What sequence should be used as the reference for genes that are non-functional in some humans? For the first question, we propose to include all genes that are functional even in one individual to produce a maximally-inclusive set of genes. For the second, we propose the use of the ancestral allele as the reference allele. This will provide a uniform basis for gene annotation and ensure that the reference gene set and sequence will be relatively stable as more individual genomes are sequenced. In the few cases where an ancestral state assignment is unavailable or ambiguous, we propose that genes be annotated as the functional allele.
221 Natural history of chronic liver disease (CLD) in the dionysos cohort by ten years of follow-up
Authors: L. Miglioli, F. Masutti, L. Croce, G. Bedogni, A. Castiglione, L. Visintin, C. Campello, G. Dal Molin, C. Tiribelli, S. Bellentani
Journal: Journal of Hepatology (2004)
Further experience with transcatheter closure of the patent ductus arteriosus using the Amplatzer duct occluder
Authors: Basil (Vasilios) D Thanopoulos, Fakhri A Hakim, Aktham Hiari, Yousef Goussous, Evangelia Basta, Armine A Zarayelyan, George S Tsaousis
Journal: Journal of the American College of Cardiology (2000)
Clinicopathological pattern of lymph node recurrence of papillary thyroid cancer. Implications for surgery
Authors: Giovanni Conzo, Claudio Mauriello, Giovanni Docimo, Claudio Gambardella, Guglielmo Thomas, Fabio Cavallo, Ernesto Tartaglia, Salvatore Napolitano, Roerto Varriale, Gianluca Rossetti, Landino Fei, Luigi Santini
Journal: International Journal of Surgery (2014)
Abstract 5372: Dendritic-cell based vaccine for advanced pancreatic cancer: A report of 39 cases treated in Seren Clinic Nagoya
Authors: Masanori Kobayashi, Tomoyo Sakabe, Shigehiro Kure, Masato Okamoto, Kiyoshi Yokokawa
Journal: Cancer Research (2012)

Abstract Objective: In the current study, we retrospectively assessed the efficacy of dendritic cell (DC)-based vaccine in advanced pancreatic carcinoma (PC). Patients: From Jan 2009 to April 2010, 39 patients (19 males and 20 females; aged 32-78 years, median 64 years) with advanced PC were treated with DC-based vaccine, and 38 patients also received GEM and/or S-1. Methods: Patient-derived peripheral blood mononuclear cells were obtained by leukapheresis (400ml×13 cycles), then adherent cells were cultured with GM-CSF, IL-4, OK-432 and PGE2 to generate DCs. The DCs pulsed with tumor specific peptides (WT1/MUC1) were injected at 2-week intervals (mean=8.3, max= 16 vaccinations). Results: The mean observation period was 257.6 days. None of the 39 patients showed CR, but we have found out 9 cases of PR and 9 cases of SD in accordance with RECIST. Response rate was 55% in the patients in combination with S-1+GEM and 9% with GEM alone. Disease control rate was 77.8% with S-1+GEM and 38% with GEM alone. Conclusions: DC-based vaccination in combined with GEM/S-1 was shown to be safe and possibly effective in patients with advanced pancreatic cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5372. doi:1538-7445.AM2012-5372